Thermo Fisher (TMO) has signed a definitive agreement with Becton Dickinson (BDX) under which Thermo Fisher will acquire BD’s advanced bioprocessing business. This business combines a technical services program with a variety of peptones that enhance cell culture media formulations to improve yield and reduce variability in biopharmaceutical applications. BD’s advanced bioprocessing business has annualized revenue of approximately $100M and will be integrated into Thermo Fisher’s life sciences solutions segment. The transaction is subject to customary closing conditions and is expected to close in early 2019.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.